GlassScriptPhysician profile
Robert Nicholas Tiballi
NPI 1194757427
$19,244.86
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,178 · 2020: $258 · 2021: $475 · 2022: $17K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $17,808.36 | 2021-2022 | |
| Melinta Therapeutics, LLC | $454.09 | 2019-2020 | |
| Allergan, INC. | $252.63 | 2019 | |
| Merck Sharp & Dohme LLC | $161.63 | 2019-2020 | |
| Gilead Sciences, INC. | $114.40 | 2019 | |
| Viiv Healthcare Company | $107.95 | 2019-2020 | |
| Janssen Biotech, INC. | $91.15 | 2019-2020 | |
| Insmed, INC. | $70.30 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $47.05 | 2019-2020 | |
| Shire North American Group INC | $34.24 | 2019 | |
| Philips North America LLC | $21.92 | 2019 | |
| Mayne Pharma Commercial LLC | $20.21 | 2019 | |
| Horizon Therapeutics Plc | $18.68 | 2019 | |
| Nabriva Therapeutics, Plc | $16.56 | 2020 | |
| Romark Laboratories, Lc | $13.02 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $12.67 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tiballi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.